Showing 4331-4340 of 5771 results for "".
- Preliminary Results From Aldeyra’s Phase 3 Tranquility Trial Offer Promise for Patients With Dry Eye Syndrome, Says GlobalDatahttps://modernod.com/news/preliminary-results-from-aldeyras-phase-3-tranquility-trial-offer-promise-for-patients-with-dry-eye-syndrome-says-globaldata/2478786/Aldeyra Therapeutics recently announced topline results from the run-in cohort of the phase 3 trial evaluating reproxalap 0.25% for patients with dry eye syndrome (DES). The positive impact of the therapy on endpoints, such as ocular dryness, discomfort and Schirmer’s test, although preliminary,
- Ocular Therapeutix Presents Interim Topline Data from the Phase 1 Clinical Trial of OTX-TIC in Patients With Glaucomahttps://modernod.com/news/ocular-therapeutix-presents-interim-topline-data-from-the-phase-1-clinical-trial-of-otx-tic-in-patients-with-glaucoma/2478784/Ocular Therapeutix announced plans to present data on OTX-TIC, a travoprost intracameral implant for the treatment of patients with primary open angle glaucoma or ocular hypertension, at the Glaucoma 360 New Horizons Forum being held virtually on January 30. As part of the event, Michael Goldstei
- Alcon Launches Precision1 for Astigmatism Contact Lenses in the UShttps://modernod.com/news/alcon-launches-precision1-for-astigmatism-contact-lenses-in-the-us/2478780/Alcon announced the US launch of Precision1 for Astigmatism, a daily disposable, silicone hydrogel (SiHy) contact lens designed for astigmatic patients. “Precision1, with its cutting-edge Smartsurface technology, has become the fastest-growing daily disposable contact lens brand in the U.S
- Oxurion NV Appoints Prof Alan Stitt as Chief Scientific Officerhttps://modernod.com/news/oxurion-nv-appoints-prof-alan-stitt-as-chief-scientific-officer/2478775/Oxurion has announced the appointment of Professor Alan Stitt, PhD, as the company’s Chief Scientific Officer (CSO), effective January 19, 2021. This appointment follows the retirement of current CSO Jean Feyen, PhD, who has served in this position since joining the company in 2013. Dr. Feyen wil
- RightEye Launches New Version 4.0 to its Eye Tracking Technologyhttps://modernod.com/news/righteye-launches-new-version-4-0-to-its-eye-tracking-technology/2478777/RightEye announced the launch of its Version 4.0 update to the RightEye Vision System. This update offers three improvements including a new dynamic vision assessment module, an expanded and updated reference population dataset, and a modern dashboard and user interface. The new Dynamic Vi
- Rayner Enters Canadian Ophthalmology Markethttps://modernod.com/news/rayner-enters-canadian-ophthalmology-market/2478773/Following the recent approval of incorporation, Rayner announced that is will now be offering the Rayner portfolio of IOLs and injectors directly to Canadian surgeons. The entry into the Canadian market will be led by Wade Allen, Director: Americas, Rayner Surgical Corp. The RayOne Aspheri
- Bausch + Lomb Completes Enrollment Of First Phase 3 Study For NOV03 (Perfluorohexyloctane)https://modernod.com/news/bausch-lomb-completes-enrollment-of-first-phase-3-study-for-nov03-perfluorohexyloctane/2478770/Bausch + Lomb and Novaliq announced the first of two phase 3 studies evaluating NOV03 as a first-in-class investigational drug with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD) has been completely enrolled w
- Neurophth and AAVnerGene Enter Strategic Partnership for Next-Generation Ophthalmic Gene Therapyhttps://modernod.com/news/neurophth-and-aavnergene-enter-strategic-partnership-for-next-generation-ophthalmic-gene-therapy/2478771/Neurophth Therapeutics, a subsidiary of Wuhan Neurophth Biotechnology gene therapy company, and AAVnerGene, an AAV technology company, announced a strategic partnership to provide Neurophth with worldwide rights to mutually select adeno-associated virus (AAV) capsids for the next generation ophth
- Biden Picks Former FDA Commissioner David Kessler to Lead Operation Warp Speedhttps://modernod.com/news/biden-picks-former-fda-commissioner-david-kessler-to-lead-operation-warp-speed/2478768/US President-elect Joe Biden announced a number of appointments to the incoming team handling the response to the COVID-19 pandemic, including naming David Kessler as chief science officer. Mr. Kessler, who served as FDA commissioner between 1990 and 1997, will reportedly share oversight of Opera
- James Reid Named CEO of Versant Healthhttps://modernod.com/news/james-reid-named-ceo-of-versant-health/2478762/MetLife announced that James Reid has been named CEO of Versant Health, a managed vision care company and wholly owned subsidiary of MetLife. The appointment is effective April 1. “James brings extensive and varied experience in the Group Benefits market to Versant Health,” Todd Katz, chai